Foreign News

24th analytica 2014 Closes With Outstanding Results in All Areas


MUNICH: The 24th analytica, the international trade fair for laboratory technology, analysis and biotechnology, was held at the Munich Trade Fair Centre, Germany from April 1-4, 2014. The fair attracted a total of 34,400 visitors (as compared to 30,481 in 2012); out of which 12,000 international visitors attended the expo at Munich. An increase of 25 per cent over 2012 in foreign visitors was even higher than the increase in those from Germany.

 


According to a survey by the market research institute, TNS Infratest, visitors gave 98 per cent rating of good to excellent for the exhibition and were really satisfied with the results of the fair. Seeing a clear sign, Dr Reinhardt Pfeiffer, Deputy CEO of Messe München, organizers of the trade fair, on the sidelines of the show, expressed, “The larger share of international visitors confirms and strengthens analytica’s character as a leading international trade fair.” The countries with the largest number of visitors in the following order were: Austria, Switzerland, Italy, Great Britain, USA and China. The most significant increases were among non- European countries such as China, Korea and USA.

 


Around 1,142 companies from 40 countries participated, which is the largest number of exhibitors in analytica’s history, as compared to 1,026 in 2012, an increase of 11.3 per cent. The increase was primarily the result of growth in the sectors for biotechnology and laboratory technology. Moreover, the share of international exhibitors increased by 4.8 per cent to 39.8 per cent. Besides Germany, the countries with the largest number of exhibitors were the USA, Great Britain, China, Switzerland and France. A large number of international exhibitors were represented by the upper management. According to a survey by TNS Infratest, satisfaction among exhibitors was also at record levels. They primarily praised the fair’s character as a leading exhibition and the advantages that it offers over other events.

 


One of the exhibitors, Hanna Engelhardt, Marketing-Life Science of Analytik Jena AG, Germany remarked, “Once again, we were able to make a large number of new contacts at this year’s fair. The visitors who attend analytica come from various branches of the industry, which makes it the right fair for us. Our company does business at the global level, so the large share of international visitors here is also very advantageous. We had visitors from a number of different countries including Algeria, the USA and many others.” On the other hand, Nils Garnebode, Department Head-Project Support and Marketing, Shimadzu, Germany said, “analytica is a good opportunity to meet with customers and competitors and, thus, is an industry gathering in the truest sense. Once again, the fair’s international character is clearly visible with visitors from Europe and the entire world.”

 


Tom Keppeler, Public Relations Leader, Thermo Fisher Scientific, USA, informed, “analytica 2014 was a huge success for three of the company’s premier brands. The event is our biggest European show and we love the opportunity to show customers, press, analysts and the general public a few of our latest instruments, equipments, consumables and software to such a broad audience. Our booths welcomed visitors from nearly every country in Europe, as well as three other continents.” Extremely happy with the event, Marc Sommer, Marketing Manager-Exhibitions & Events, asecos GmbH, Germany expressed, “Our daily presentations at the Live Lab area were a popular visitor attraction. Focusing on the topic of occupational safety is valuable for the fair, something that was confirmed by several of the visitors who attended the presentations! We will definitely be represented again at the next analytica and would be pleased to continue helping to shape this focused topic.”

 


International growth at the analytica conference


The analytica Conference, which had a large number of participants, also contributed to the fair’s record-breaking results. Prof (Dr) Wolfram Koch, Managing Director of the German Chemical Society (GDCh) and a member of the team that organizes the conference remarked, “Right now, the analytica Conference is certainly one of the most important conferences in the context of analytical sciences — and not just in the German-speaking region, but also in Europe and increasingly at the global level. Among other things, that is noticeable by the fact that the number of participants from non-European countries continues to increase.” Chairs and spokespeople from Europe, China, Australia and the USA made presentations on hot topics such as leading coupling & separating techniques, drug & food analysis and chemometric methods. Despite larger rooms, many of the lectures were filled to capacity. One highlight was the session titled “Service to Mankind: The Changing Faces of Analytical Chemistry”, which was possible thanks to transatlantic collaboration between the German and American trade associations, i.e. the GDCh and the American Chemical Society (ACS).


Related events program


The special show on ‘Occupational Safety / Health and Safety at the Workplace’ was a huge success from the very beginning. 14 per cent of all visitors attended the show to find out how to protect themselves from hazards in the laboratory. The Live Labs, which were already a popular event among visitors in 2012, saw even more visitor traffic at this year’s fair.


The industry will meet again in Shanghai on October 16, 2014 for analytica China. Besides China, the global analytica network is represented in the future markets of India and Vietnam. The next analytica will take place in Munich from May 10-13, 2016.

 


DUPHAT Concludes with More Than 18,000 Visitors and AED600 Million of Business


DUBAI: The nineteenth edition of the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT) concluded on March 12, 2014, at the Dubai International Convention and Exhibition Centre. “More than 18,000 visitors & participants and business deals worth more than AED 600 million were concluded during the three-day Expo,” according to Tariq Al Madani, Managing Director of INDEX Conferences and Exhibitions, the organizers of the event. “This reveals the success of DUPHAT and the leading role of Dubai in organising prestigious conferences and exhibitions with high efficiency in terms of participants and attendees. The majority of exhibitors at DUPHAT have confirmed booking their space for next year’s show as well,” he said on the sidelines of the expo.


Shaikh Ahmed bin Saeed Al Maktoum, President of Dubai Civil Aviation Authority, Chairman of Dubai Airports and Chairman & Chief Executive of Emirates Airlines and Group, inaugurated the trade show. Shaikh Ahmed was accompanied by Eng. Essa Al Maidoor, Director-General of Dubai Health Authority (DHA) and a number of local & international representatives & heads of delegations. Following the traditional inauguration ceremony and the ribbon-cutting, Shaikh Ahmed announced that Dubai would host for the first time the International Family Medicine (IFM) Conference and Exhibition, which will be held next year in conjunction with DUPHAT. “IFM conference and exhibition will attract an enormous number of specialists in family medicine, general practitioners and primary healthcare,” he informed. Congratulating the organizing committee for the success achieved by the event since it was launched, Shaikh Ahmed emphasized, “DUPHAT is a continuing education forum and platform for professional interaction and scientific discourse.” Being impressed by the continuous growth that the event is achieving every year, he said, “This tremendous turnout reinforces the role of Dubai as a regional hub for major international companies who are looking forward to promoting their products from Dubai to the Middle East and the world markets.”

 


DUPHAT conference this year hosted 24 scientific sessions and 21 workshops that were presented by 72 speakers on various topics including critical elements for developing ambulatory care, clinical pharmacy services, 7 habits of highly effective pharmacists, pharmacotherapy of addiction, evolving trends in pharmacy education, advances in pharmacy practice across states and evolving trends in pharmacy education. At the end of the third day, the scientific committee released the following recommendations of the conference:

  • Encourage field studies to reveal unpublished medical effects with the aim to broaden its therapeutic uses.
  • Encourage meetings and task forces between pharmaceutical industry & health authorities and authorize pharmacists to resolve situations of unavailability of medicines in terms of defining reasons and finding alternative options.
  • Increase patient awareness in good storage practices of medicines to maintain its quality and effectiveness during the usage period and utilize media resources to spread awareness.
  • Maximize the expertise and scope of pharmacists to involve expanded role in patient care services.
  • Spotlighting the developments and new technologies in human resources field to prepare a new generation for dealing professionally with the problems of this era, taking into consideration the humanitarian needs in solving the problems related to pharmaceutical services and industries and new therapeutic methods and incorporating the pharmacists’ role in the medical team to provide necessary advices in optimal use of technologies.
  • Involve standards of pharmacy practices to include the changing needs and demands of contemporary care across all settings in inpatients and outpatients.
  • Encourage pharmacists’ participation in reporting and treating all adverse drug reactions and medication errors related to use of medications which include:
    • Continuous professional training,
    • Communication and coordination with medical team within the facility,
    • Measure the positive outcomes achieved from reporting, and
    • Spread awareness between all medical crew to adhere to using medical prescriptions.
  • Address multifaceted regular monitoring and evaluation of pharmacy domains of practice to guarantee uninterrupted and continued public access to medicines with international measures of quality and safety.
  • Enforce and implement stakeholders and social engagement in pharmacy sector through public-private-partnership, patient involvement and community based programs for the sake of patients’ welfare & public health.


    On the sidelines of the event, an award ceremony was also held to honour the participants, organizers and sponsors of DUPHAT. The ceremony was attended by heads of delegates and members of the scientific committee. Essa Al Maidoor distributed the awards and expressed his gratitude for all those who contributed to the success of the event.

 


Mylan Q4 Profit Rises 11 Percent to $180 Million


PITTSBURGH: US generic major Mylan Inc., on February 28, 2014, reported that fourth-quarter (Q4) profits for the three months ended December 31, 2013 rose 11 per cent, to $180.2 million compared with $162 million in the corresponding quarter of previous financial year. Total revenue for Q4 was $1.81 billion ($1.72 billion), an increase of 5 per cent; while earnings per-share (EPS) profits climbed 15 per cent to $0.45 ($0.39). The company earned total revenue of $6.91 billion for the year ended December 31, 2013, compared with $6.80 billion in the corresponding previous financial year, thus showing an increase of 2 per cent. This was despite the fact that the new product revenues in 2013 was 69 per cent lower at $285 million as compared to $922 million in 2012. Adjusted diluted Earnings Per Share (EPS) rose 12 per cent to $2.89 for the year ended December 31, 2013, from $2.59 for the same prior year period.

 


Ms Heather Bresch, chief executive of Mylan commented, “2013 demonstrated the strength of our diverse, global platform and showcased our ability to effectively execute on our business to deliver on the key financial metrics we set, including double-digit bottom-line growth. 2013 also saw us hit meaningful milestones in our key growth drivers, including our injectables, respiratory, infectious disease, complex products and biologics programs." She added, "Our ability to deliver continued strong growth was particularly noteworthy given the unprecedented year we had in 2012 in terms of new product launches, as compared to 2013 during which we saw several key product approvals delayed. These delays will add to the many opportunities we have ahead in 2014, which combined with our continued commitment to strong execution, gives us great confidence in our expectations of 16 per cent growth in revenues and 19 per cent growth in adjusted diluted EPS for the year."

 


John Sheehan, Mylan’s CFO, added, “Our focus on execution in 2013 enabled us to once again produce solid financial results for our shareholders. Mylan’s ability to generate strong cash flow provided us with the flexibility to return another $1 billion to shareholders in 2013, bringing our total share repurchases to approximately $2.4 billion throughout the past three years. As we move into 2014, we expect that our financial flexibility will provide further opportunities to expand our business in strategic areas and create additional value for our shareholders." He further emphasized, "We look forward to continuing to leverage our unique global operating and commercial platform and identifying additional opportunities for growth as we progress towards our long-term financial targets, including our target of adjusted diluted EPS of atleast $6 by the end of 2018.”

 


Despite the negative impact of currency fluctuation and the lacklustre performance of newly launched products, Mylan recorded growth on the back of strong sales in the specialty segment. Mylan reports revenues from two segments, viz. generics and specialty. Third party net revenues from generics segment were $5.87 billion in the year ended December 31, 2013, compared to $5.91 billion in the comparable prior year period, representing a decrease of $40 million, or 1 per cent. Third-party net revenues from generics segment, derived from sales in North America, Europe, the Middle East & Africa (collectively, “EMEA”) and Rest of World, climbed 4.5 per cent to $1.62 billion in Q4, compared to $1.55 billion in the comparable prior year period, representing an increase of $64.2 million.

 


Third party net revenues from specialty segment were $981.7 million in the year ended December 31, 2013, compared to $835.4 million in the comparable prior year period, representing an increase of $146.3 million, or 17.6 per cent. Third-party net revenues from specialty segment climbed 13 per cent to $176.1 million in Q4, compared to $155.9 million in the comparable prior year period, representing an increase of $20.2 million. Specialty segment sales were driven by the strong performance of its flagship product – EpiPen auto-injector – for severe allergic reactions. Favourable pricing and volume-aided sales of the product in Q4, which is the number one dispensed epinephrine auto-injector. Mylan and Pfizer have an agreement for EpiPen, under which Pfizer manufactures and Mylan markets the product. In addition, Perforomist® Inhalation Solution sales increased by double digits from the comparable prior year period, as a result of favourable pricing.

 


Apart from releasing its earnings results, Mylan provided guidance for 2014. The company expects adjusted earnings in the range of $3.25-3.60 per share, up 19 per cent year-on-year. The company expects revenues in the range of $7.8-8.2 billion, up 16 per cent. Mylan, which acquired Agila Specialties (the injectable drugs division of India’s Strides Arcolab) for $1.6 billion in 2013 to strengthen its presence in the high potential generic injectables market, expects to make another meaningful transaction in 2014.

 


PMMI Opens Registration for Debut Edition of Pharma Expo 2014


RESTON (VIRGINIA): The Association for Packaging and Processing Technologies (PMMI), a trade association representing over 600 packaging and processing supply chain companies, and the International Society for Pharmaceutical Engineers (ISPE), the world’s largest not-for-profit association serving its members through leading scientific, technical and regulatory advancement throughout the entire pharmaceutical lifecycle, have announced open registration for Pharma Expo 2014, to be held at Chicago, USA from November 2-5, 2014. Co-located with Pack Expo International, the debut edition of Pharma Expo will bring over 200 exhibitors and 10,000 attendees together and provide exposure to innovative technologies, education sessions and an exchange of ideas across different sectors of the pharma industry.

 


In a statement, Charles D. Yuska, President & CEO, PMMI commented, “The support from the pharma industry has been excellent.” He added, “We still have seven months before Pharma Expo and Pack Expo International open, and we’ve already exceeded projections for space sales and exhibiting companies.” Ms Nancy Berg, President & CEO, ISPE, noted, “ISPE prepares members to lead global change and innovation in pharma manufacturing sciences and technologies.” Regarding the event, she said, “A robust conference program will complement the exhibits at Pharma Expo. Educational sessions will cover critical topics such as anti-counterfeiting, international regulatory issues, automation trends, cold chain, nutraceuticals, contract packaging, overall equipment effectiveness and global supply chain serialization.” She finally concluded, “As our attendees cross between the two events, they’ll carry a wealth of new ideas with them.”

 


The tradeshow will also feature “Innovation Stage” presentations, which will provide additional educational opportunities on the show floor, including ISPE’s Facility of the Year Award (FOYA) that will mark the award’s 10th anniversary this year. “Visitors will find the FOYA showcase set-up at the entrance to the West Hall exhibits of Pharma Expo,” informed the organizers in a press release.

 


Videojet Launches Information-Rich Global Website


CHICAGO (ILLINOIS): Videojet Technologies Inc., a world-leading manufacturer of coding and printing technologies for the pharmaceutical, industrial and consumer packaged goods industries, has announced the release of its new website on March 6, 2014. The new website has been designed to help manufacturers worldwide to understand the full range of company’s coding & printing solutions available, access detailed product information and explore industry & application-specific information & resources.

 


The new website, created with customers’ needs firmly in mind, was designed to ensure Videojet’s extensive portfolio of solutions is easy to browse, while also improving navigation and overall usability. As part of Videojet’s ongoing commitment to engage customers and provide them with information and services to help achieve their distinct business goals, the new site has been designed to be compatible with the latest generation of Internet browsers and is regularly updated with industry and product-specific technical information, videos, case studies, white papers and much more. “Videojet partners with customers across the globe to improve their operational reliability and productivity. Our new information-rich website is a natural extension of our focus on maximizing customer interaction, thus, providing not only essential product information but also a wealth of industry and solution-based material that can be accessed and shared at any time,” said Chris Riley, Vice President of Marketing, Videojet Technologies.

 

The new website features a live support centre that provides immediate assistance in local languages. The website users will be able to interact with customer support specialists, assured that their query is answered and dealt with a professional & swift manner. Riley added, “We recognize that when in need, people want answers as soon as possible. This is why we made providing our customers with immediate support a key element of our new site, and yet another example of our continued investment to making the lives of our customers easier wherever possible.” He finally concluded, “The new website is just another example of our sustained investment in informing and supporting customers. We have an immense passion to partner with our customers’ and as such the new website – has been designed through a collaborative approach with clients. This is just one of the ways we are making ourselves available to help them make the right choices for their business.”

 

 

 

 

 

 

Subscription